Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid?

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 8, 2010, Pages 803-807

  Jentink, Janneke ^a,b   Bakker, Marian K ^b   Nijenhuis, Cynthia M ^a   Wilffert, Bob ^a   De Jong van Den Berg, Lolkje T W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Case control study; Folic acid; Pregnancy; Spina bifida; Valproic acid

Indexed keywords

FOLIC ACID; VALPROIC ACID;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DECISION TREE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; PRENATAL DRUG EXPOSURE; PREVALENCE; PRIORITY JOURNAL; REGISTER; RISK REDUCTION; SPINA BIFIDA; VITAMIN SUPPLEMENTATION;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; CASE-CONTROL STUDIES; DIETARY SUPPLEMENTS; FEMALE; FOLIC ACID; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RISK FACTORS; SPINAL DYSRAPHISM; VALPROIC ACID;

EID: 77956644487     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1975     Document Type: Article

References (38)

1. Eichholzer M, Tönz O, Zimmermann R. Folic acid: a public-health challenge. Lancet 2006; 367: 1352-1361.
2. De Walle HEK, Reefhuis J, Cornel MC. Folic acid prevents more than neural tube defects: a registry-based study in the northern Netherlands. Eur J Epidemiol 2003; 18: 279-280. (Pubitemid 36597149)
3. Gezondheidsraad. Risico's van foliumzuurverrijking (Health Council. Risks of fortification with folic acid). Den Haag 2000; publication number 2000/21 (in Dutch).
4. De Wals P, Tairou F, Van Allen MI, et al. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007; 357: 135-142.
5. Ray JG. Folic acid food fortification in Canada. Nutr Rev 2004; 62(6,II): S35-S39. (Pubitemid 38916078)
6. Craig J, Morrison P, Morrow J, Patterson V. Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure 1999; 8: 253-254. (Pubitemid 29401594)
7. Hernandez-Diaz S, Werler MM, Walker AM, Mitchel AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Eng J Med 2000; 343: 1608-1614. (Pubitemid 32162984)
8. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003; 60: 575-579. (Pubitemid 36246072)
9. Morrow JI, Hunt SJ, Russell AJ, et al. Folic acid and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2009; 80: 506-511.
10. Cornel MC, DeWalle HEK, Zandwijken GRJ, Anthony S, Ten Kate LP. De geschiedenis van de registratie en frequentiebewaking van aangeboren afwijkingen in Nederland (The history of the registry and frequency monitoring of congenital malformations in the Netherlands). Tijdschr Gezondheidswet 2008; 86(2): 86-91 (in Dutch).
11. EUROCAT website. Available at: http://www.eurocatnederland.nl (in Dutch), [3 November 2008].
12. Reefhuis J, De Walle HEK, De Jong-van denBerg LTW, Cornel MC, EuroMAP-group. Additional information from parental questionnaires and pharmacy records for registration of birth defects. Eur J Epidemiol 2000; 16: 329-336.
13. Goh YI, Bollano E, Einarson TR, Koren G. Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis. J Obstet Gynaecol Can 2006; 28(8): 680.
14. Apeland T, Mansoor MA, Strandjord RE. Antiepileptic drugs as independent predictors of plasma total homocysteine levels. Epilepsy Res 2001; 47: 27-35. (Pubitemid 32973645)
15. Kishi T, Fujita N, Eguchi T, Ueda K. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci 1997; 145: 109-112. (Pubitemid 27141588)
16. Schwaninger M, Ringleb P, Winter R, et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 1999; 43(3): 345-350.
17. Candito M, Naimi M, Boisson C, et al. Plasma vitamin values and antiepileptic therapy: case reports of pregnancy outcomes affected by a neural tube defect. Birth Defects Res A Clin Mol Teratol 2007; 79: 62-64.
18. Duncan S, Mercho S, Lopes-Cendes I, et al. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia 2001; 42(6): 750-753.
19. Van Allen MI, Kalousek K, Chernoff GF, et al. Evidence for multi-site closure of the neural tube in humans. Am J Med Genet 1993; 47: 723-743.
20. Ahmad FU, Mahapatra AK. Neural tube defects at separate sites: further evidence in support of multi-site closure of the neural tube in humans. Surg Neurol 2009; 71: 353-356.
21. Kibar Z, Capra V, Gros P. Toward understanding the genetic basis of neural tube defects. Clin Genet 2007; 71: 295-310.
22. Nakatsu T, Uwabe C, Shiota K. Neural tube closure in humans initiates at multiple sites: evidence from human embryos and implications for pathogenesis of neural tube defects. Anat Embryol 2000; 201: 455-466.
23. Harden CL, Meador KJ, Pennell PB, et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes. Epilepsia 2009;50(5): 1237-1246.
24. Elmazar MMA, Thiel T, Nau H. Effect of supplementation with folic acid, vitamin B6, and vitamin B12 on valproic acid-induced teratogenesis in mice. Fundam Appl Toxicol 1992; 18: 389-394.
25. Essien FB,Wannberg SL. Methionine but not folic acid or vitamin B12 alters the frequency of neural tube defects in Axd mutant mice. J Nutr 1993; 123: 27-34.
26. Hansen DK, Grafton TF, Dial SL, Gehring TA, Sitonen PH. Effect of supplemental folic acid on valproic acid-induced embryo toxicity and tissue zinc levels in vivo. Teratology 1995; 52: 277-285.
27. Trotz M, Wegner S, Nau H. Valproic acid-induced neural tube defects: reduction by folic acid in the mouse. Life Sci 1987; 41: 103-110.
28. Wegner C, Nau H. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis. Neurology 1992; 42 (Suppl. 5): 17-24.
29. Elmazar MMA, Nau H. Methotrexate increases valproic acid-induced developmental toxicity, in particular neural tube defects in mice. Teratog Carcinog Mutagen 1992; 12: 203-210.
30. Ehlers K, Elmazar MMA, Nau H. Mehionine reduces the valproic acid-induced spina bifida rate in mice without altering valproic acid kinetics. J Nutr 1996; 126: 67-75.
31. Greene NDE, Copp AJ. Mouse models of neural tube defects: investigating preventive mechanisms. Am J Med Genet C Semin Med Genet 2005; 135C: 31-41.
32. Yerby MS. Teratogenicity and antiepileptic drugs: potential mechanisms. Int Rev Neurobiol 2008; 83: 181-204.
33. Hishida R, Nau H. VPA-Induced neural tube defects in mice. I. Altered metabolims of sulfur amino acids and glutathione. Teratog Carcinog Mutagen 1998; 18: 49-61.
34. Úbeda N, Alonso-Aperta E, Varela-Moreiras G. Acute valproate administration impairs methionine metabolism in rats. J Nutr 2002; 132: 2737-2742.
35. Kostrouchová M, Kostrouch Z, Kostrouchová M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha) 2007; 53: 37-49.
36. Harden CL, Pennell PB, Koppel BS. et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast feeding. Epilepsia 2009; 50(5): 1247-1255.
37. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009; 360: 1597-1605.
38. Winterbottom J, Smyth R, Jacoby A, Baker G. The effectiveness of preconception counseling to reduce adverse pregnancy outcome in women with epilepsy: What's the evidence? Epilepsy Behav 2009; 14: 273-279.